Heart Failure Market

According to Stratistics MRC, the Global Heart Failure Market is accounted for $18.5 billion in 2026 and is expected to reach $31.2 billion by 2034 growing at a CAGR of 6.7% during the forecast period. The Heart Failure Market focuses on pharmaceutical therapies, medical devices, and specialized healthcare solutions for managing heart failure, a chronic condition characterized by the heart's inability to pump or fill adequately to meet the body's circulatory requirements. Increasing prevalence of cardiovascular diseases, aging populations, and rising hospitalization rates are supporting market expansion. Advancements in SGLT2 inhibitors, angiotensin receptor-neprilysin inhibitors, cardiac monitoring systems, and implantable devices are improving treatment approaches. Growing healthcare expenditure, early diagnosis initiatives, and expanding access to specialized cardiac care are further encouraging market development worldwide.

Market Dynamics:

Driver:

Increasing prevalence of cardiovascular diseases and aging populations

The increasing prevalence of cardiovascular diseases and the growing geriatric population are major drivers of the heart failure market. Conditions such as coronary artery disease, hypertension, diabetes, and cardiomyopathy contribute significantly to heart failure development. Rising life expectancy and improved survival following cardiovascular events are increasing the number of individuals requiring long-term heart failure management. Greater awareness of early diagnosis, improved access to cardiac imaging, and expanding adoption of guideline-directed medical therapies are supporting treatment demand. Continued investment in cardiovascular healthcare infrastructure is further encouraging market growth.

Restraint:

High treatment costs and limited access to specialized cardiac care

High treatment costs and unequal access to specialized cardiac services are significant restraints on market expansion. Advanced medications, implantable cardiac devices, repeated hospitalizations, and long-term disease monitoring can create substantial financial burdens for patients and healthcare systems. Limited reimbursement coverage and inadequate specialist availability in developing regions may restrict access to effective treatment. Additionally, complex medication regimens, treatment-related adverse effects, and poor patient adherence can reduce therapeutic effectiveness. Differences in healthcare infrastructure and delayed diagnosis further complicate comprehensive heart failure management.

Opportunity:

Advancements in targeted therapies and remote cardiac monitoring technologies

Advancements in cardiovascular therapeutics and remote patient monitoring are creating significant opportunities for market participants. Increasing adoption of SGLT2 inhibitors, ARNIs, and other guideline-directed medications is improving treatment options across different heart failure categories. Wearable sensors, implantable monitoring devices, and digital health platforms enable more frequent assessment of patient status and may support earlier intervention. Pharmaceutical companies are also investigating novel mechanisms targeting cardiac function and disease progression. Expanding telecardiology services and personalized treatment strategies are further encouraging innovation and investment.

Threat:

Regulatory complexities and competitive pressure from generic medications

Stringent regulatory requirements, pricing pressures, and increasing competition from generic medications present significant market threats. Developers of new heart failure therapies and implantable devices must demonstrate clinical safety, effectiveness, and long-term outcomes through extensive evaluation. Patent expirations and generic competition may reduce revenues for established pharmaceutical products. Device-related complications, medication intolerance, and inconsistent reimbursement policies can also influence treatment adoption. Additionally, supply chain disruptions, healthcare budget constraints, and variations in clinical practice may create operational challenges for manufacturers and healthcare providers.

Covid-19 Impact:

The COVID-19 pandemic affected the heart failure market through disruptions in routine cardiovascular consultations, diagnostic procedures, and elective interventions. Patients with existing heart failure faced increased clinical risks from severe infection, while healthcare systems experienced pressure on hospital capacity and specialist services. Delayed medical evaluations and interruptions in disease monitoring complicated chronic heart failure management. However, telemedicine, remote cardiac monitoring, and home-based care gained importance during the pandemic. Subsequent recovery in cardiovascular services and continued adoption of digital healthcare solutions supported market stabilization and long-term development.

The heart failure with reduced ejection fraction (HFrEF) segment is expected to be the largest during the forecast period

The heart failure with reduced ejection fraction (HFrEF) segment is expected to account for the largest market share during the forecast period due to its substantial treatment requirements and established use of multiple evidence-based therapies. HFrEF management commonly involves ARNIs or other renin-angiotensin system inhibitors, beta blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Patients with advanced disease may also require implantable cardiac devices and specialized interventions. Continued adoption of guideline-directed medical therapy, improved diagnostic capabilities, and increasing availability of advanced treatment options are supporting segment development.

The SGLT2 inhibitors segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the SGLT2 inhibitors segment is predicted to witness the highest growth rate due to expanding clinical use of these medications in heart failure management. Originally developed for type 2 diabetes, SGLT2 inhibitors have demonstrated cardiovascular benefits in appropriate patients with heart failure, including those with reduced or preserved ejection fraction. Their inclusion in major treatment guidelines is supporting broader physician adoption. Increasing awareness of cardiorenal benefits, growing treatment eligibility, and continued clinical research are encouraging demand. Pharmaceutical investment and expanding access to these therapies may further support segment growth.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share, supported by advanced cardiovascular healthcare infrastructure, substantial healthcare expenditure, and widespread availability of innovative heart failure treatments. The United States represents a major market due to significant cardiovascular disease burden, established cardiac specialty centers, and strong pharmaceutical and medical device industries. Increasing adoption of guideline-directed therapies, implantable devices, and remote monitoring technologies is supporting market development. Continued clinical research activity and access to specialized cardiac care further strengthen regional performance.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR due to increasing cardiovascular disease prevalence, rapidly aging populations, and expanding healthcare infrastructure. China, India, Japan, South Korea, and Australia are important markets for heart failure diagnosis and treatment. Rising healthcare expenditure, improving access to cardiac specialists, and growing adoption of advanced pharmaceutical therapies are supporting demand. Government initiatives to strengthen cardiovascular healthcare services, increasing medical device availability, and expanding telemedicine capabilities are further encouraging regional market growth.

Key players in the market

Some of the key players in the Heart Failure Market include Novartis, AstraZeneca, Boehringer Ingelheim, Bayer, Merck & Co., Eli Lilly and Company, Cytokinetics, Amgen, Bristol-Myers Squibb, Abbott, Medtronic, Boston Scientific, Biotronik, Novo Nordisk, and Pfizer.

Key Developments:

In June 2026, the U.S. Food and Drug Administration approved a revised post-approval study protocol for Abbott's CardioMEMS HF System. The implantable pulmonary artery pressure monitoring system supports remote management of eligible heart failure patients by providing hemodynamic information to clinicians.

In November 2025, Bayer announced that Kerendia (finerenone) received approval in India for treating adults with heart failure with preserved or mildly reduced ejection fraction. The therapy is a non-steroidal, selective mineralocorticoid receptor antagonist supported by clinical evidence from the FINEARTS-HF study.

In July 2025, Bayer announced U.S. FDA approval of Kerendia (finerenone) for adults with heart failure and a left ventricular ejection fraction of at least 40%. The approval was based on the Phase III FINEARTS-HF study, which demonstrated reductions in cardiovascular death and total heart failure events.

Heart Failure Types Covered:
• Heart Failure with Reduced Ejection Fraction (HFrEF)
• Heart Failure with Preserved Ejection Fraction (HFpEF)
• Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)

Disease Severities Covered:
• NYHA Class I
• NYHA Class II
• NYHA Class III
• NYHA Class IV

Etiologies Covered:
• Ischemic Heart Failure
• Hypertensive Heart Failure
• Valvular Heart Failure
• Cardiomyopathy-Associated Heart Failure
• Congenital Heart Disease-Associated Heart Failure
• Other Etiologies

Drug Classes Covered:
• ACE Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)
• Beta Blockers
• Mineralocorticoid Receptor Antagonists (MRAs)
• SGLT2 Inhibitors
• Diuretics
• Vasodilators
• Inotropes
• Other Drug Classes

Routes of Administration Covered:
• Oral
• Injectable

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End Users Covered:
• Hospitals
• Cardiac Specialty Centers
• Ambulatory Surgical Centers
• Home Care Settings

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances